Canntab & FSD Pharma Make Cannabis More Palatable for Doctors

Cannabinoids have the potential to radically transform the pharmaceutical industry. For example, new studies suggest that cannabis legalization could reduce opioid prescriptions by about six to 12 percent. The problem is that medical cannabis is very different from pharmaceutical drugs—it’s hard for physicians to prescribe treatments that lack consistency or may be metabolized differently between patients.

Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.

In this article, we will look at Canntab’s partnership strategy, which could open the door to near-term revenue opportunities.

Near-term Revenue Potential

Canntab submitted an application to become a licensed producer under the ACMPR back in October. Once the license is granted, the company will be able to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures compared to a new purpose-built facility. The application is a step in the right direction, but could take months for Health Canada to review and approve the application.

In the meantime, the company partnered with FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) in September to begin manufacturing its tablets. The agreement calls for FSD Pharma to assist Canntab in obtaining a license to sell cannabis and provide space at its Cobourg facility near Toronto. Canntab will in turn provide all of the necessary equipment and provide a royalty on products that are manufactured within the facility.

The company delivered manufacturing equipment to FSD Pharma’s Cobourg plant in September that will enable the production of more than 1.5 million tablets per day. Under the terms of the deal, these products will be sold by both FSD Pharma—where it receives half of all profit from sales through its channels—or through Canntab’s channels—where FSD Pharma will receive 3.5 percent of the selling price.

Building Value with Partners

Canntab’s partnership with FSD Pharma is just one of several partnerships that the company has signed over the past several months.

The company’s other partnerships include

• Dr. Don Garbuz, MD: The company signed a binding term sheet with Dr. Garbuz, a leading orthopedic surgeon, to conduct a clinical study on his patients using Canntab’s sustained release tablets for pain reduction.
• Emblem Corp. (TSX-V: EMC) (OTC: EMMBF): The company is collaborating with Emblem to formulate its cannabinoid-based product portfolio. Dissolution testing indicated that its extended release tablets deliver over 12 hours.
• Labsco Promedic SA: The company agreed to form a joint venture with Labsco Promedic to distribute its products in Mexico.

The agreements expand the company’s distribution into parts of Latin America and Europe, as well as pave the way for robust clinical data to support its claims to reduce pain and operate over an extended period of time.

Looking Ahead

Canntab Therapeutics Ltd. (CSE: PILL) (TBF1.F) represents a compelling investment opportunity. By providing doctors with a better way to prescribe cannabis, the company’s products could open the door to a much larger addressable patient population. The near-term agreement with FSD Pharma helps get products into the market, while numerous distribution agreements could lead to near-term commercialization opportunities.

For more information, visit the company’s website.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.